Evidence map›Paper›PMID 35595858›Full record

ArticleScientific reports2022

Proof of concept for multiplex amplicon sequencing for mutation identification using the MinION nanopore sequencer.

Whitney Whitford, Victoria Hawkins, Kriebashne S Moodley, Matthew J Grant, Klaus Lehnert, Russell G Snell, Jessie C Jacobsen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. mtDNA analysis using Mitopore.Molecular therapy. Methods & clinical development · 2024
    Article
  16. Novel PHOTOPERIOD-1 gene variants associate with yield-related and root-angle traits in European bread wheat.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Whitney WhitfordSchool of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. whitney.whitford@auckland.ac.nz.
Victoria HawkinsSchool of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Kriebashne S MoodleySchool of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Matthew J GrantSchool of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Klaus LehnertSchool of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Russell G SnellSchool of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
Jessie C JacobsenSchool of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.
University of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid, cost-effective identification of genetic variants in small candidate genomic regions remains a challenge, particularly for less well equipped or lower throughput laboratories. The application of Oxford Nanopore Technologies' MinION sequencer has the potential to fulfil this requirement. We demonstrate a proof of concept for a multiplexing assay that pools PCR amplicons for MinION sequencing to enable sequencing of multiple templates from multiple individuals, which could be applied to gene-targeted diagnostics. A combined strategy of barcoding and sample pooling was developed for simultaneous multiplex MinION sequencing of 100 PCR amplicons. The amplicons are family-specific, spanning a total of 30 loci in DNA isolated from 82 human neurodevelopmental cases and family members. The target regions were chosen for further interrogation because a potentially disease-causative variant had been identified in affected individuals following Illumina exome sequencing. The pooled MinION sequences were deconvoluted by aligning to custom references using the minimap2 aligner software. Our multiplexing approach produced an interpretable and expected sequence from 29 of the 30 targeted genetic loci. The sequence variant which was not correctly resolved in the MinION sequence was adjacent to a five nucleotide homopolymer. It is already known that homopolymers present a resolution problem with the MinION approach. Interestingly despite equimolar quantities of PCR amplicon pooled for sequencing, significant variation in the depth of coverage (127×-19,626×; mean = 8321×, std err = 452.99) was observed. We observed independent relationships between depth of coverage and target length, and depth of coverage and GC content. These relationships demonstrate biases of the MinION sequencer for longer templates and those with lower GC content. We demonstrate an efficient approach for variant discovery or confirmation from short DNA templates using the MinION sequencing device. With less than 130 × depth of coverage required for accurate genotyping, the methodology described here allows for rapid highly multiplexed targeted sequencing of large numbers of samples in a minimally equipped laboratory with a potential cost as much 200 × less than that from Sanger sequencing.

Indexed as

Nanopore SequencingSequence Analysis, DNAGenomicsHigh-Throughput Nucleotide SequencingHumansMutation

Identifiers

PMID35595858
PMCPMC9122479
OpenAlexW4281263647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.